Pathology Doctors in Mason City, IA Accepting Medicare

4 Pathology doctors found. Showing 1 - 4

Dr. David Christian Sloan, M.D. Pathology - Anatomic Pathology & Clinical Pathology Medicare: Accepting Medicare Assignments Practice Location: 1000 4th St Sw, Mason City, IA 50401 Phone: 641-422-7488    Fax: 641-422-7988

Dr. Stephen Anthony Betz, M.D. Pathology - Anatomic Pathology & Clinical Pathology Medicare: Accepting Medicare Assignments Practice Location: 1000 4th St Sw, Mason City, IA 50401 Phone: 641-422-7488    Fax: 641-422-7988

Mrs. Jean Marie Coviello, D.O. Pathology - Anatomic Pathology & Clinical Pathology Medicare: Accepting Medicare Assignments Practice Location: 1408 6th St Sw, Mason City, IA 50401 Phone: 641-423-3903

Angela Dawn Konrad, DO Pathology - Anatomic Pathology & Clinical Pathology Medicare: Accepting Medicare Assignments Practice Location: 1000 4th St Sw, Mason City, IA 50401 Phone: 641-428-7488

News Archive

Intraoperative angiography ‘valuable' in vascular brain surgery

Use of intraoperative angiography often leads to surgical revision during treatment of brain vascular abnormalities, say researchers.

Cellular Biomedicine Group gets approval to conduct ReJoin Phase IIb trial for Knee Osteoarthritis

Cellular Biomedicine Group, Inc., a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that it has received approval to conduct a Phase IIb clinical trial for ReJoin, a human adipose-derived mesenchymal precursor cells (haMPC) therapy bio-engineered for Knee Osteoarthritis.

Creating hair-bearing human skin becomes a reality

For more than 40 years, scientists and commercial companies have been recreating human skin in laboratories around the world. Yet all of these products lack important aspects of normal skin-hair, nerves, and fat.

Combination of lapatinib and trastuzumab more effective in treating HER2-positive breast cancer

Using two drugs that inhibit the growth factor HER2 for preoperative treatment of early-stage HER2-positive breast cancer appears to have better results than treatment with a single agent. In a report in the January 17 issue of The Lancet, an international research team reports that a protocol adding lapatinib (Tykerb) to trastuzumab (Herceptin) was more effective than single-drug treatment with either drug in eliminating microscopic signs of cancer at the time the tumors were surgically removed.

Study findings could lead to new potential drug targets for allergic diseases

Scientists have discovered over 30 new genes that predispose people to allergies and asthma, some of which could be targets for new drugs.

Read more Medical News

› Verified 4 days ago